On June 5, Kelun-Biotech rose 3.54% in regular trading, trading at HK$406.2/share, with trading volume of HK$30.125 million.

On the news front, the company announced on June 4 a proposal to seek shareholder approval authorizing the board to repurchase up to 10% of its issued H shares, sending a positive signal to the market. Additionally, its core product sac-TMT (SKB264/MK-2870) Phase III OptiTROP-Lung05 study results were recently presented as an oral report at the ASCO annual meeting and simultaneously published in The Lancet, demonstrating a PFS hazard ratio of 0.35 in PD-L1 positive non-small cell lung cancer — the first ADC globally to show PFS improvement in this indication.

The stock had previously been under pressure due to widening net losses and consecutive share disposals by the chairman. The buyback plan combined with landmark clinical data is helping restore market sentiment and rebuild investor confidence in the companys long-term pipeline value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)